Cefuroxime axetil (oral): Difference between revisions
No edit summary |
No edit summary |
||
| Line 26: | Line 26: | ||
'''| [[Cefuroxime axetil overdosage|Overdosage]]''' | '''| [[Cefuroxime axetil overdosage|Overdosage]]''' | ||
'''| [[Cefuroxime axetil dosage and administration|Dosage and Administration]]''' | '''| [[Cefuroxime axetil dosage and administration|Dosage and Administration]]''' | ||
'''| [[Cefuroxime axetil | '''| [[Cefuroxime axetil clinical studies|Clinical Studies]]''' | ||
'''| [[Cefuroxime axetil how supplied|How Supplied]]''' | '''| [[Cefuroxime axetil how supplied|How Supplied]]''' | ||
'''| [[Cefuroxime axetil labels and packages|Labels and Packages]]''' | '''| [[Cefuroxime axetil labels and packages|Labels and Packages]]''' | ||
Revision as of 04:50, 6 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
Overview
Cefuroxime axetil is a second generation oral cephalosporin antibiotic. It was discovered by Glaxo now GlaxoSmithKline and introduced in 1987 asZinnat.[1] It was approved by FDA on Dec 28, 1987.[2] It is available by GSK as Ceftin in US
It is an acetoxyethyl ester prodrug of cefuroxime which is effective orally.The activity depends on in vivo hydrolysis and release of cefuroxime.
Category
Cephalosporins, second generation.
US Brand Names
CEFTIN®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Dosage and Administration | Clinical Studies | How Supplied | Labels and Packages
References
http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050605s042lbl.pdf